Download PDF
Semin Respir Crit Care Med 2015; 36(05): 650-661
DOI: 10.1055/s-0035-1562892
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Role of Non-Culture-Based Tests, with an Emphasis on Galactomannan Testing for the Diagnosis of Invasive Aspergillosis

Marisa H. Miceli
1   Division of Infectious Diseases, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan
,
Johan Maertens
2   Acute Leukemia and Stem Cell Transplantation Unit, Universitaire Ziekenhuizen Leuven, Campus Gasthuisberg, Catholic University, Leuven, Belgium
› Author Affiliations
Further Information

Publication History

Publication Date:
23 September 2015 (online)

    Permissions and Reprints

Abstract

An established diagnosis of invasive aspergillus is seldom achieved premortem. Conventional laboratory diagnostic methods such as culture and microscopy, although very useful when positive, are insensitive and time-consuming, resulting in late diagnosis and treatment and contributing to high mortality rates. As a result, routine antifungal prophylaxis and early empirical treatment have been recommended. The use of sensitive and rapid non-culture-based diagnostic assays for the detection of Aspergillus antigens (using commercially available tests to detect galactomannan and 1, 3 β-D-glucan) or detection of genomic DNA sequences may allow a shift in emphasis from empirical to preemptive therapy, especially when substantiated by suggestive radiological findings. These new tools may be used to confirm a presumed diagnosis of invasive aspergillosis, or, when used to screen high-risk patients, may identify an infection at an early stage of disease. Their excellent negative predictive value should convince clinicians to withhold antifungal therapy in patients with no other signs of fungal disease. On the other hand, consecutive positive results should at least trigger a complete diagnostic workup. This article will review the diagnostic utility as well as the pitfalls of using these non-culture-based tools for diagnosing invasive aspergillosis.

Keywords

galactomannan - beta-D-glucan - polymerase chain reaction - Aspergillus - diagnosis - preemptive
 

  • References

  • 1 Thompson III GR, Patterson TF. Pulmonary aspergillosis. Semin Respir Crit Care Med 2008; 29 (2) 103-110
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34 (7) 909-917
    CrossrefPubMedGoogle Scholar
  • 3 De Pauw B, Walsh TJ, Donnelly JP , et al; European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46 (12) 1813-1821
    CrossrefPubMedGoogle Scholar
  • 4 Meersseman W, Lagrou K, Maertens J, Van Wijngaerden E. Invasive aspergillosis in the intensive care unit. Clin Infect Dis 2007; 45 (2) 205-216
    CrossrefPubMedGoogle Scholar
  • 5 von Eiff M, Roos N, Schulten R, Hesse M, Zühlsdorf M, van de Loo J. Pulmonary aspergillosis: early diagnosis improves survival. Respiration 1995; 62 (6) 341-347
    CrossrefPubMedGoogle Scholar
  • 6 Caillot D, Couaillier JF, Bernard A , et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 2001; 19 (1) 253-259
    CrossrefPubMedGoogle Scholar
  • 7 Hope WW, Walsh TJ, Denning DW. Laboratory diagnosis of invasive aspergillosis. Lancet Infect Dis 2005; 5 (10) 609-622
    CrossrefPubMedGoogle Scholar
  • 8 Rinaldi MG. Problems in the diagnosis of invasive fungal diseases. Rev Infect Dis 1991; 13 (3) 493-495
    CrossrefPubMedGoogle Scholar
  • 9 Boudewijns M, Verweij PE, Melchers WJ. Molecular diagnosis of invasive aspergillosis: the long and winding road. Future Microbiol 2006; 1 (3) 283-293
    CrossrefPubMedGoogle Scholar
  • 10 Mennink-Kersten MA, Verweij PE. Non-culture-based diagnostics for opportunistic fungi. Infect Dis Clin North Am 2006; 20 (3) 711-727 , viii
    CrossrefPubMedGoogle Scholar
  • 11 Ascioglu S, Rex JH, de Pauw B , et al; Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer; Mycoses Study Group of the National Institute of Allergy and Infectious Diseases. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34 (1) 7-14
    CrossrefPubMedGoogle Scholar
  • 12 Guinea J, Bouza E. Current challenges in the microbiological diagnosis of invasive aspergillosis. Mycopathologia 2014; 178 (5-6) 403-416
    CrossrefPubMedGoogle Scholar
  • 13 Morton CO, Loeffler J, De Luca A , et al. Dynamics of extracellular release of Aspergillus fumigatus DNA and galactomannan during growth in blood and serum. J Med Microbiol 2010; 59 (Pt 4) 408-413
    CrossrefPubMedGoogle Scholar
  • 14 Hope WW, Kruhlak MJ, Lyman CA , et al. Pathogenesis of Aspergillus fumigatus and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis: implications for antifungal therapy. J Infect Dis 2007; 195 (3) 455-466
    CrossrefPubMedGoogle Scholar
  • 15 Chamilos G, Luna M, Lewis RE , et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica 2006; 91 (7) 986-989
    PubMedGoogle Scholar
  • 16 Lewis RE, Kontoyiannis DP. Invasive aspergillosis in glucocorticoid-treated patients. Med Mycol 2009; 47 (Suppl. 01) S271-S281
    CrossrefPubMedGoogle Scholar
  • 17 Barton RC. Laboratory diagnosis of invasive aspergillosis: from diagnosis to prediction of outcome. Scientifica (Cairo) 2013; 2013: 459405
    PubMedGoogle Scholar
  • 18 Galactomannan - Food and Drug Administration - http://www.accessdata.fda.gov/cdrh_docs/pdf9/K093678.pdf 2011 . Accessed on January 26, 2013
    PubMed
  • 19 Serum Galactomannan- Food and Drug Administration http://www.accessdata.fda.gov/cdrh_docs/pdf6/K060641.pdf 2006 . Accessed on January 26, 2013
    PubMed
  • 20 Galactomannan - Food and Drug Administration - Regulatory Information. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM420248.pdf 2015
    PubMedGoogle Scholar
  • 21 Zou M, Tang L, Zhao S , et al. Systematic review and meta-analysis of detecting galactomannan in bronchoalveolar lavage fluid for diagnosing invasive aspergillosis. PLoS ONE 2012; 7 (8) e43347
    CrossrefPubMedGoogle Scholar
  • 22 Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 2006; 42 (10) 1417-1427
    CrossrefPubMedGoogle Scholar
  • 23 Horn DL, Freifeld AG, Schuster MG, Azie NE, Franks B, Kauffman CA. Treatment and outcomes of invasive fusariosis: review of 65 cases from the PATH Alliance(®) registry. Mycoses 2014; 57 (11) 652-658
    CrossrefPubMedGoogle Scholar
  • 24 Vergidis P, Walker RC, Kaul DR , et al. False-positive Aspergillus galactomannan assay in solid organ transplant recipients with histoplasmosis. Transpl Infect Dis 2012; 14 (2) 213-217
    CrossrefPubMedGoogle Scholar
  • 25 Maertens J.A., Personal Communication, February 2015
    PubMed
  • 26 Tortorano AM, Esposto MC, Prigitano A , et al. Cross-reactivity of Fusarium spp. in the Aspergillusgalactomannan enzyme-linked immunosorbent assay. J Clin Microbiol 2012; 50 (3) 1051-1053
    CrossrefPubMedGoogle Scholar
  • 27 Walsh TJ, Anaissie EJ, Denning DW , et al; Infectious Diseases Society of America. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46 (3) 327-360
    CrossrefPubMedGoogle Scholar
  • 28 Mori Y, Nagasaki Y, Kamezaki K , et al. High incidence of false-positive Aspergillus galactomannan test in multiple myeloma. Am J Hematol 2010; 85 (6) 449-451
    PubMedGoogle Scholar
  • 29 Odabasi Z, Mattiuzzi G, Estey E , et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004; 39 (2) 199-205
    CrossrefPubMedGoogle Scholar
  • 30 Iwanaga S, Miyata T, Tokunaga F, Muta T. Molecular mechanism of hemolymph clotting system in Limulus. Thromb Res 1992; 68 (1) 1-32
    PubMedGoogle Scholar
  • 31 Karageorgopoulos DE, Vouloumanou EK, Ntziora F, Michalopoulos A, Rafailidis PI, Falagas ME. β-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin Infect Dis 2011; 52 (6) 750-770
    CrossrefPubMedGoogle Scholar
  • 32 Marty FM, Koo S. Role of (1—>3)-beta-D-glucan in the diagnosis of invasive aspergillosis. Med Mycol 2009; 47 (Suppl. 01) S233-S240
    CrossrefPubMedGoogle Scholar
  • 33 Marchetti O, Lamoth F, Mikulska M, Viscoli C, Verweij P, Bretagne S ; European Conference on Infections in Leukemia (ECIL) Laboratory Working Groups. ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients. Bone Marrow Transplant 2012; 47 (6) 846-854
    CrossrefPubMedGoogle Scholar
  • 34 Lamoth F, Cruciani M, Mengoli C , et al; Third European Conference on Infections in Leukemia (ECIL-3). β-Glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the Third European Conference on Infections in Leukemia (ECIL-3). Clin Infect Dis 2012; 54 (5) 633-643
    CrossrefPubMedGoogle Scholar
  • 35 Mengoli C, Cruciani M, Barnes RA, Loeffler J, Donnelly JP. Use of PCR for diagnosis of invasive aspergillosis: systematic review and meta-analysis. Lancet Infect Dis 2009; 9 (2) 89-96
    CrossrefPubMedGoogle Scholar
  • 36 Kourkoumpetis TK, Fuchs BB, Coleman JJ, Desalermos A, Mylonakis E. Polymerase chain reaction-based assays for the diagnosis of invasive fungal infections. Clin Infect Dis 2012; 54 (9) 1322-1331
    CrossrefPubMedGoogle Scholar
  • 37 Bašková L, Buchta V. Laboratory diagnostics of invasive fungal infections: an overview with emphasis on molecular approach. Folia Microbiol (Praha) 2012; 57 (5) 421-430
    CrossrefPubMedGoogle Scholar
  • 38 Wang Y, Chen L, Liu X , et al. Detection of Aspergillus fumigatus pulmonary fungal infections in mice with (99m)Tc-labeled MORF oligomers targeting ribosomal RNA. Nucl Med Biol 2013; 40 (1) 89-96
    CrossrefPubMedGoogle Scholar
  • 39 Cramer Jr RA, Gamcsik MP, Brooking RM , et al. Disruption of a nonribosomal peptide synthetase in Aspergillus fumigatus eliminates gliotoxin production. Eukaryot Cell 2006; 5 (6) 972-980
    CrossrefPubMedGoogle Scholar
  • 40 Pinto LJ, Moore MM. Screening method to identify inhibitors of siderophore biosynthesis in the opportunistic fungal pathogen, Aspergillus fumigatus . Lett Appl Microbiol 2009; 49 (1) 8-13
    CrossrefPubMedGoogle Scholar
  • 41 Thornton CR. Development of an immunochromatographic lateral-flow device for rapid serodiagnosis of invasive aspergillosis. Clin Vaccine Immunol 2008; 15 (7) 1095-1105
    CrossrefPubMedGoogle Scholar
  • 42 Hoenigl M, Koidl C, Duettmann W , et al. Bronchoalveolar lavage lateral-flow device test for invasive pulmonary aspergillosis diagnosis in haematological malignancy and solid organ transplant patients. J Infect 2012; 65 (6) 588-591
    CrossrefPubMedGoogle Scholar
  • 43 Thornton C, Johnson G, Agrawal S. Detection of invasive pulmonary aspergillosis in haematological malignancy patients by using lateral-flow technology. J Vis Exp 2012; (61)
    PubMedGoogle Scholar
  • 44 Hoenigl M, Prattes J, Spiess B , et al. Performance of galactomannan, beta-d-glucan, Aspergillus lateral-flow device, conventional culture, and PCR tests with bronchoalveolar lavage fluid for diagnosis of invasive pulmonary aspergillosis. J Clin Microbiol 2014; 52 (6) 2039-2045
    CrossrefPubMedGoogle Scholar
  • 45 Willinger B, Lackner M, Lass-Flörl C , et al. Bronchoalveolar lavage lateral-flow device test for invasive pulmonary aspergillosis in solid organ transplant patients: a semiprospective multicenter study. Transplantation 2014; 98 (8) 898-902
    CrossrefPubMedGoogle Scholar
  • 46 Held J, Schmidt T, Thornton CR, Kotter E, Bertz H. Comparison of a novel Aspergillus lateral-flow device and the Platelia® galactomannan assay for the diagnosis of invasive aspergillosis following haematopoietic stem cell transplantation. Infection 2013; 41 (6) 1163-1169
    CrossrefPubMedGoogle Scholar
  • 47 White PL, Parr C, Thornton C, Barnes RA. Evaluation of real-time PCR, galactomannan enzyme-linked immunosorbent assay (ELISA), and a novel lateral-flow device for diagnosis of invasive aspergillosis. J Clin Microbiol 2013; 51 (5) 1510-1516
    CrossrefPubMedGoogle Scholar
  • 48 Maertens JA, Klont R, Masson C , et al. Optimization of the cutoff value for the Aspergillus double-sandwich enzyme immunoassay. Clin Infect Dis 2007; 44 (10) 1329-1336
    CrossrefPubMedGoogle Scholar
  • 49 Leeflang MM, Debets-Ossenkopp YJ, Visser CE , et al. Galactomannan detection for invasive aspergillosis in immunocompromized patients. Cochrane Database Syst Rev 2008; (4) CD007394
    PubMedGoogle Scholar
  • 50 Maertens J, Verhaegen J, Lagrou K, Van Eldere J, Boogaerts M. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 2001; 97 (6) 1604-1610
    CrossrefPubMedGoogle Scholar
  • 51 Sulahian A, Boutboul F, Ribaud P, Leblanc T, Lacroix C, Derouin F. Value of antigen detection using an enzyme immunoassay in the diagnosis and prediction of invasive aspergillosis in two adult and pediatric hematology units during a 4-year prospective study. Cancer 2001; 91 (2) 311-318
    CrossrefPubMedGoogle Scholar
  • 52 Maertens J, Van Eldere J, Verhaegen J, Verbeken E, Verschakelen J, Boogaerts M. Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients. J Infect Dis 2002; 186 (9) 1297-1306
    CrossrefPubMedGoogle Scholar
  • 53 Klont RR, Mennink-Kersten MA, Verweij PE. Utility of Aspergillus antigen detection in specimens other than serum specimens. Clin Infect Dis 2004; 39 (10) 1467-1474
    CrossrefPubMedGoogle Scholar
  • 54 Guo YL, Chen YQ, Wang K, Qin SM, Wu C, Kong JL. Accuracy of BAL galactomannan in diagnosing invasive aspergillosis: a bivariate metaanalysis and systematic review. Chest 2010; 138 (4) 817-824
    CrossrefPubMedGoogle Scholar
  • 55 Hage CA, Reynolds JM, Durkin M, Wheat LJ, Knox KS. Plasmalyte as a cause of false-positive results for Aspergillus galactomannan in bronchoalveolar lavage fluid. J Clin Microbiol 2007; 45 (2) 676-677
    CrossrefPubMedGoogle Scholar
  • 56 Racil Z, Kocmanova I, Toskova M , et al. Galactomannan detection in bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in patients with hematological diseases-the role of factors affecting assay performance. Int J Infect Dis 2011; 15 (12) e874-e881
    CrossrefPubMedGoogle Scholar
  • 57 Verdaguer V, Walsh TJ, Hope W, Cortez KJ. Galactomannan antigen detection in the diagnosis of invasive aspergillosis. Expert Rev Mol Diagn 2007; 7 (1) 21-32
    CrossrefPubMedGoogle Scholar
  • 58 Penack O, Rempf P, Graf B, Blau IW, Thiel E. Aspergillus galactomannan testing in patients with long-term neutropenia: implications for clinical management. Ann Oncol 2008; 19 (5) 984-989
    CrossrefPubMedGoogle Scholar
  • 59 Bergeron A, Belle A, Sulahian A , et al. Contribution of galactomannan antigen detection in BAL to the diagnosis of invasive pulmonary aspergillosis in patients with hematologic malignancies. Chest 2010; 137 (2) 410-415
    CrossrefPubMedGoogle Scholar
  • 60 Becker MJ, Lugtenburg EJ, Cornelissen JJ, Van Der Schee C, Hoogsteden HC, De Marie S. Galactomannan detection in computerized tomography-based broncho-alveolar lavage fluid and serum in haematological patients at risk for invasive pulmonary aspergillosis. Br J Haematol 2003; 121 (3) 448-457
    CrossrefPubMedGoogle Scholar
  • 61 Musher B, Fredricks D, Leisenring W, Balajee SA, Smith C, Marr KA. Aspergillus galactomannan enzyme immunoassay and quantitative PCR for diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid. J Clin Microbiol 2004; 42 (12) 5517-5522
    CrossrefPubMedGoogle Scholar
  • 62 Luong ML, Filion C, Labbé AC , et al. Clinical utility and prognostic value of bronchoalveolar lavage galactomannan in patients with hematologic malignancies. Diagn Microbiol Infect Dis 2010; 68 (2) 132-139
    CrossrefPubMedGoogle Scholar
  • 63 Antinori S, Corbellino M, Meroni L , et al. Aspergillus meningitis: a rare clinical manifestation of central nervous system aspergillosis. Case report and review of 92 cases. J Infect 2013; 66 (3) 218-238
    CrossrefPubMedGoogle Scholar
  • 64 Verweij PE, Brinkman K, Kremer HP, Kullberg BJ, Meis JF. Aspergillus meningitis: diagnosis by non-culture-based microbiological methods and management. J Clin Microbiol 1999; 37 (4) 1186-1189
    PubMedGoogle Scholar
  • 65 Viscoli C, Machetti M, Gazzola P , et al. Aspergillus galactomannan antigen in the cerebrospinal fluid of bone marrow transplant recipients with probable cerebral aspergillosis. J Clin Microbiol 2002; 40 (4) 1496-1499
    CrossrefPubMedGoogle Scholar
  • 66 Duettmann W, Koidl C, Troppan K , et al. Serum and urine galactomannan testing for screening in patients with hematological malignancies. Med Mycol 2014; 52 (6) 647-652
    CrossrefPubMedGoogle Scholar
  • 67 Miller-Hjelle MA, Hjelle JT, Jones M , et al. Polycystic kidney disease: an unrecognized emerging infectious disease?. Emerg Infect Dis 1997; 3 (2) 113-127
    CrossrefPubMedGoogle Scholar
  • 68 Verweij PE, Weemaes CM, Curfs JH, Bretagne S, Meis JF. Failure to detect circulating Aspergillus markers in a patient with chronic granulomatous disease and invasive aspergillosis. J Clin Microbiol 2000; 38 (10) 3900-3901
    PubMedGoogle Scholar
  • 69 Silveira FP, Husain S. Fungal infections in lung transplant recipients. Curr Opin Pulm Med 2008; 14 (3) 211-218
    CrossrefPubMedGoogle Scholar
  • 70 Grossi P, Farina C, Fiocchi R, Dalla Gasperina D ; Italian Study Group of Fungal Infections in Thoracic Organ Transplant Recipients. Prevalence and outcome of invasive fungal infections in 1,963 thoracic organ transplant recipients: a multicenter retrospective study. Transplantation 2000; 70 (1) 112-116
    PubMedGoogle Scholar
  • 71 Gavalda J, Len O, San Juan R , et al; RESITRA (Spanish Network for Research on Infection in Transplantation). Risk factors for invasive aspergillosis in solid-organ transplant recipients: a case-control study. Clin Infect Dis 2005; 41 (1) 52-59
    CrossrefPubMedGoogle Scholar
  • 72 Park SY, Lim C, Lee SO , et al. Computed tomography findings in invasive pulmonary aspergillosis in non-neutropenic transplant recipients and neutropenic patients, and their prognostic value. J Infect 2011; 63 (6) 447-456
    CrossrefPubMedGoogle Scholar
  • 73 Cahill BC, Hibbs JR, Savik K , et al. Aspergillus airway colonization and invasive disease after lung transplantation. Chest 1997; 112 (5) 1160-1164
    CrossrefPubMedGoogle Scholar
  • 74 Tabarsi P, Soraghi A, Marjani M , et al. Comparison of serum and bronchoalveolar lavage galactomannan in diagnosing invasive aspergillosis in solid-organ transplant recipients. Exp Clin Transplant 2012; 10 (3) 278-281
    CrossrefPubMedGoogle Scholar
  • 75 Husain S, Kwak EJ, Obman A , et al. Prospective assessment of Platelia Aspergillus galactomannan antigen for the diagnosis of invasive aspergillosis in lung transplant recipients. Am J Transplant 2004; 4 (5) 796-802
    CrossrefPubMedGoogle Scholar
  • 76 Husain S, Paterson DL, Studer SM , et al. Aspergillus galactomannan antigen in the bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in lung transplant recipients. Transplantation 2007; 83 (10) 1330-1336
    CrossrefPubMedGoogle Scholar
  • 77 Luong ML, Clancy CJ, Vadnerkar A , et al. Comparison of an Aspergillus real-time polymerase chain reaction assay with galactomannan testing of bronchoalvelolar lavage fluid for the diagnosis of invasive pulmonary aspergillosis in lung transplant recipients. Clin Infect Dis 2011; 52 (10) 1218-1226
    CrossrefPubMedGoogle Scholar
  • 78 Clancy CJ, Jaber RA, Leather HL , et al. Bronchoalveolar lavage galactomannan in diagnosis of invasive pulmonary aspergillosis among solid-organ transplant recipients. J Clin Microbiol 2007; 45 (6) 1759-1765
    CrossrefPubMedGoogle Scholar
  • 79 Pasqualotto AC, Xavier MO, Sánchez LB , et al. Diagnosis of invasive aspergillosis in lung transplant recipients by detection of galactomannan in the bronchoalveolar lavage fluid. Transplantation 2010; 90 (3) 306-311
    PubMedGoogle Scholar
  • 80 Cai X, Ni W, Wei C, Cui J. Diagnostic value of the serum galactomannan and (1, 3)-β-D-glucan assays for invasive pulmonary aspergillosis in non-neutropenic patients. Intern Med 2014; 53 (21) 2433-2437
    CrossrefPubMedGoogle Scholar
  • 81 Montagna MT, Caggiano G, Lovero G , et al. Epidemiology of invasive fungal infections in the intensive care unit: results of a multicenter Italian survey (AURORA Project). Infection 2013; 41 (3) 645-653
    CrossrefPubMedGoogle Scholar
  • 82 Koulenti D, Garnacho-Montero J, Blot S. Approach to invasive pulmonary aspergillosis in critically ill patients. Curr Opin Infect Dis 2014; 27 (2) 174-183
    CrossrefPubMedGoogle Scholar
  • 83 Acosta J, Catalan M, del Palacio-Peréz-Medel A , et al. A prospective comparison of galactomannan in bronchoalveolar lavage fluid for the diagnosis of pulmonary invasive aspergillosis in medical patients under intensive care: comparison with the diagnostic performance of galactomannan and of (1→ 3)-β-d-glucan chromogenic assay in serum samples. Clin Microbiol Infect 2011; 17 (7) 1053-1060
    CrossrefPubMedGoogle Scholar
  • 84 Blyth DM, Chung KK, Cancio LC, King BT, Murray CK. Clinical utility of fungal screening assays in adults with severe burns. Burns 2013; 39 (3) 413-419
    CrossrefPubMedGoogle Scholar
  • 85 Guinea J, Torres-Narbona M, Gijón P , et al. Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: incidence, risk factors, and outcome. Clin Microbiol Infect 2010; 16 (7) 870-877
    CrossrefPubMedGoogle Scholar
  • 86 Fukuda T, Boeckh M, Carter RA , et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 2003; 102 (3) 827-833
    CrossrefPubMedGoogle Scholar
  • 87 Meersseman W, Vandecasteele SJ, Wilmer A, Verbeken E, Peetermans WE, Van Wijngaerden E. Invasive aspergillosis in critically ill patients without malignancy. Am J Respir Crit Care Med 2004; 170 (6) 621-625
    CrossrefPubMedGoogle Scholar
  • 88 He H, Ding L, Li F, Zhan Q. Clinical features of invasive bronchial-pulmonary aspergillosis in critically ill patients with chronic obstructive respiratory diseases: a prospective study. Crit Care 2011; 15 (1) R5
    CrossrefPubMedGoogle Scholar
  • 89 Meersseman W, Lagrou K, Maertens J , et al. Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients. Am J Respir Crit Care Med 2008; 177 (1) 27-34
    CrossrefPubMedGoogle Scholar
  • 90 Ruhnke M, Böhme A, Buchheidt D , et al; Infectious Diseases Working Party in Haematology and Oncology of the German Society for Haematology and Oncology. Diagnosis of invasive fungal infections in hematology and oncology—guidelines from the Infectious Diseases Working Party in Haematology and Oncology of the German Society for Haematology and Oncology (AGIHO). Ann Oncol 2012; 23 (4) 823-833
    CrossrefPubMedGoogle Scholar
  • 91 Freifeld AG, Bow EJ, Sepkowitz KA , et al; Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011; 52 (4) e56-e93
    CrossrefPubMedGoogle Scholar
  • 92 Duarte RF, Sánchez-Ortega I, Cuesta I , et al. Serum galactomannan-based early detection of invasive aspergillosis in hematology patients receiving effective antimold prophylaxis. Clin Infect Dis 2014; 59 (12) 1696-1702
    CrossrefPubMedGoogle Scholar
  • 93 Eiden C, Palenzuela G, Hillaire-Buys D , et al. Posaconazole-increased vincristine neurotoxicity in a child: a case report. J Pediatr Hematol Oncol 2009; 31 (4) 292-295
    CrossrefPubMedGoogle Scholar
  • 94 de Pauw BE, Viscoli C. Managing invasive fungal infections: relying on clinical instincts or on a rational navigation system?. J Antimicrob Chemother 2011; 66 (Suppl. 01) i55-i58
    CrossrefPubMedGoogle Scholar
  • 95 Maertens J, Theunissen K, Verhoef G , et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005; 41 (9) 1242-1250
    CrossrefPubMedGoogle Scholar
  • 96 Morrissey CO, Bardy PG, Slavin MA , et al. Diagnostic and therapeutic approach to persistent or recurrent fevers of unknown origin in adult stem cell transplantation and haematological malignancy. Intern Med J 2008; 38 (6b): 477-495
    CrossrefPubMedGoogle Scholar
  • 97 Tan BH, Low JG, Chlebicka NL , et al. Galactomannan-guided preemptive vs. empirical antifungals in the persistently febrile neutropenic patient: a prospective randomized study. Int J Infect Dis 2011; 15 (5) e350-e356
    CrossrefPubMedGoogle Scholar
  • 98 Cordonnier C, Pautas C, Maury S , et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis 2009; 48 (8) 1042-1051
    CrossrefPubMedGoogle Scholar
  • 99 Miceli MH, Grazziutti ML, Woods G , et al. Strong correlation between serum Aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications. Clin Infect Dis 2008; 46 (9) 1412-1422
    CrossrefPubMedGoogle Scholar
  • 100 Park SH, Choi SM, Lee DG , et al. Serum galactomannan strongly correlates with outcome of invasive aspergillosis in acute leukaemia patients. Mycoses 2011; 54 (6) 523-530
    CrossrefPubMedGoogle Scholar
  • 101 Maertens J, Buvé K, Theunissen K , et al. Galactomannan serves as a surrogate endpoint for outcome of pulmonary invasive aspergillosis in neutropenic hematology patients. Cancer 2009; 115 (2) 355-362
    CrossrefPubMedGoogle Scholar
  • 102 Boutboul F, Alberti C, Leblanc T , et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: increasing antigenemia is associated with progressive disease. Clin Infect Dis 2002; 34 (7) 939-943
    CrossrefPubMedGoogle Scholar
  • 103 Woods G, Miceli MH, Grazziutti ML, Zhao W, Barlogie B, Anaissie E. Serum Aspergillus galactomannan antigen values strongly correlate with outcome of invasive aspergillosis: a study of 56 patients with hematologic cancer. Cancer 2007; 110 (4) 830-834
    CrossrefPubMedGoogle Scholar
  • 104 Segal BH, Herbrecht R, Stevens DA , et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis 2008; 47 (5) 674-683
    CrossrefPubMedGoogle Scholar